Overview

FAZA PET/MRI Sarcoma

Status:
Recruiting

Trial end date:
2022-03-01

Target enrollment:
0

Participant gender:
All

Summary

This is a single arm, single centre, investigator initiated study to investigate the use of FAZA-PET in combination with MRI. FAZA is an investigational radiotracer used in PET scans. FAZA PET/MRI will be used to measure hypoxia in sarcoma tissues of 14 patients who plan to undergo neoadjuvant radiation/chemotherapy treatment. After the FAZA PET/MRI scan, patients will be followed up via telephone, 48 hours after the scan, to see if there are any side effects due to FAZA. Patients may also be requested to repeat the FAZA scan after their standard of care radiation treatment.

Phase:

N/A

Accepts Healthy Volunteers?

Details

Lead Sponsor:

University Health Network, Toronto

Treatments:

Fluoroazomycin arabinoside

Criteria

Inclusion Criteria:

1. Age ≥ 18 years

2. Patients with either: high-risk extremity STS (g2-3, > 10 cm largest dimension, and
leiomyosarcoma, synovial sarcoma, malignant peripheral nerve sheath tumour, or
undifferentiated pleomorphic sarcoma), or: high-risk RPS (g2-3, and leiomyosarcoma or
dedifferentiated liposarcoma)

3. Intention to treat using radiotherapy/chemotherapy/surgery according to the current
treatment policies of the Sarcoma Site Group of PM

4. A negative serum pregnancy test within the two-week interval immediately prior to
PET-MR imaging, for women of child-bearing age

5. Ability to provide written informed consent to participate in the study

Exclusion Criteria:

1. Previous radiotherapy to intended treatment volumes.

2. Previous systemic therapy

3. Active malignancy other than sarcoma

4. Unable to remain supine for at least 60 minutes

5. Pregnancy or breast feeding

6. Age less than 18 years old

7. Failure to provide written informed consent

8. Contraindication for MR as per current institutional guidelines.